---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003756"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:49:14.651666+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Silexion Q3 net loss narrows to $3.3M; cash $9.2M; Phase 2/3 trial on track for H1 2026

## Summary
- Net loss $3.3M ($2.88/share) vs $11.9M ($274.25) a year ago, aided by lower share-based compensation.
- Cash and equivalents $9.2M as of Sep 30, up from $1.2M at Dec 2024, after raising ~$9.5M in Q3.
- R&D spend $2.2M (-31% YoY); G&A $1.1M (-77% YoY); shareholders' equity improved to $7.0M.
- Phase 2/3 trial of SIL204 in KRAS-driven cancers on track for H1 2026; regulatory submissions planned for Q4 2025/Q1 2026.
- New preclinical data shows SIL204 efficacy across five cancer types, including first gastric cancer evidence.

## SEC filing metadata
- accession: 0001178913-25-003756
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/0001178913-25-003756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/zk2533972.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003756
- JSON: https://secwatch.observer/filing/0001178913-25-003756.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.